ORIGINAL RESEARCH article
Front. Neurosci.
Sec. Translational Neuroscience
Volume 19 - 2025 | doi: 10.3389/fnins.2025.1542264
Targeting APE1/Ref-1 to Alleviate Formalin-Induced Pain and Spinal Neuro-Inflammation in Rats: A Promising Therapeutic Approach
Provisionally accepted
- 1Department of Biochemistry, Alexandria University, Alexandria, Egypt
- 2UMR5293 Institut des Maladies Neurodégénératives (IMN), Bordeaux, Aquitaine, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Pain is a multifaceted condition intricately linked to inflammation, which plays a critical role in its onset and progression.Methods: To investigate the influence of APE1/Ref-1 on oxidative stress and inflammatory marker expression, we employed a hind paw sensitization model induced by formalin. We inhibited the redox function of APE1 using E3330 and assessed its effects on pain behavior. Mitochondrial morphology was examined via electron microscopy, and the impact on dopaminergic signaling alongside bioinformatics analyses to explore potential E3330 binding to dopamine receptors.Results: Administration of E3330 in formalin-induced rats resulted in improved pain thresholds, as evidenced by behavioral assessments. Notably, E3330 treatment maintained normal APE1/Ref-1 levels and promoted a more organized mitochondrial structure. Administration of E3330 correlated with increased dopamine levels, a decrease in the mRNA expression of dopamine receptors DRD1 and DRD5, and a restoration of DRD2 expression in the ipsilateral spinal cords. Moreover, E3330 administration significantly reduced the expression of key inflammatory mediators including inflammasome markers. Our bioinformatics analysis using Molecular Operating Environment software indicated that E3330 possibly interacts with critical active sites within specific dopamine receptor pocket as preliminary results.These findings suggest that E3330 may modulate pain signaling pathways from the periphery to the spinal cord, offering a novel approach for the management of inflammatory pain conditions, potentially through the modulation of the dopaminergic signaling pathway. Further research is warranted to elucidate E3330's role in regulating central nervous system pain signal transmission, as it emerges as a promising therapeutic candidate in clinical contexts.
Keywords: Apurinic/apyrimidinic endonuclease 1 (APE-1/Ref-1), central nervous system (CNS), Spinal Cord, Nociception, E3330 [(2E)-2-[(4, 5-dimethoxy-2-methyl-3, 6dioxo-1, 4-cyclohexadien-1-yl) methylene]-undecanoic acid
Received: 09 Dec 2024; Accepted: 26 Jun 2025.
Copyright: © 2025 Elgendy, Zaky, Wahby, Landry and Bassiouny. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ahmad Bassiouny, Department of Biochemistry, Alexandria University, Alexandria, Egypt
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.